News Beyond Our Pages

Criner et al (N Engl J Med 2019; https://doi.org/10.1056/NEJMoa1905248) recently examined the effect of eosinophil depletion mediated by the IL-5 receptor α–blocking mAb benralizumab on the exacerbation rate of patients with chronic obstructive pulmonary disease (COPD) and high blood eosinophil counts in 2 large, complementary, phase 3, randomized controlled trials (GALATHEA and TERRANOVA). In both trials no statistically significant differences in annualized exacerbation rates were observed at any dose of benralizumab compared with placebo, despite substantial depletion of blood and sputum eosinophils.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: News beyond our pages Source Type: research